Concept study for next generation product completed

SpectraCure AB has conducted a concept study for the development of the company's technology for the treatment of prostate cancer using photodynamic therapy (PDT). 

SpectraCures current PDT system, SpectraCure P18 with IDOSE®, has evolved over a ten-year period and is currently used in a Phase 1 clinical trial for the treatment of patients with relapse of prostate cancer. Prior to product launch, this system will be updated with a modern design and improved user interface and ergonomics. This step is deemed necessary before launch, in particular to reduce the production costs of the system. Many of the components and technical solutions contained in the current system will be updated and replaced. In addition, future users expect the design and user interface to correspond to a modern medical device. 

"We are very happy to see the next generation of P18 forming" says Johannes Swartling, CTO of SpectraCure. “The progress in our clinical studies is now matched with advances in the technological design. Together with further development of the software IDOSE®, this results in the next generation of SpectraCures systems being more user friendly for hospital staff and also more adaptable to the patient’s individual conditions. This will make it easier for the doctors at the clinics to use SpectraCures systems, which is an important part of the launch”.

Prototype manufacturing will start in 2018.

For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90

SpectraCure in short

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

Read as PDF.

SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects. 

Facebook Linkedin Envelope